Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Gazzard

Showing results (161-170 of 206) with videos related to

Pageof 21
Sort By:
BMJ (Clinical Research Ed.)|March 8, 2005
Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort studyCaroline A Sabin, Teresa Hill, Fiona Lampe, et al.
The New England Journal of Medicine|January 20, 2006
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIVJoel E Gallant, Edwin DeJesus, José R Arribas, et al.
Journal of the International AIDS Society|November 14, 2014
Patient preferences for characteristics of antiretroviral therapies: results from five European countriesBrian Gazzard, Shehzad Ali, Axel Muhlbacher, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 1, 2007
Changes in outcome of persons initiating highly active antiretroviral therapy at a CD4 count less than 50 Cells/mm3Kholoud Porter, Sarah Walker, Teresa Hill, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 1, 2007
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysisJose R Arribas, Anton L Pozniak, Joel E Gallant, et al.
Antiviral Therapy|October 13, 2005
A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trialUlrik B Dragsted, Jan Gerstoft, Mike Youle, et al.
AIDS (London, England)|March 28, 2014
Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participantsFrank J Palella, Martin Fisher, Pablo Tebas, et al.
The Journal of Infectious Diseases|July 29, 2009
Virological response to initial antiretroviral regimens containing abacavir or tenofovirLoveleen Bansi, Caroline Sabin, Richard Gilson, et al.
AIDS (London, England)|June 5, 2007
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 yearsMark R Nelson, Christine Katlama, Julio S Montaner, et al.
Lancet (London, England)|December 11, 2007
Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort studyAndrew N Phillips, Clifford Leen, Alan Wilson, et al.
Pageof 21

Showing results (161-170 of 206) with videos related to

Sort By:
Pageof 21
BMJ (Clinical Research Ed.)|March 8, 2005
Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort studyCaroline A Sabin, Teresa Hill, Fiona Lampe, et al.
The New England Journal of Medicine|January 20, 2006
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIVJoel E Gallant, Edwin DeJesus, José R Arribas, et al.
Journal of the International AIDS Society|November 14, 2014
Patient preferences for characteristics of antiretroviral therapies: results from five European countriesBrian Gazzard, Shehzad Ali, Axel Muhlbacher, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 1, 2007
Changes in outcome of persons initiating highly active antiretroviral therapy at a CD4 count less than 50 Cells/mm3Kholoud Porter, Sarah Walker, Teresa Hill, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 1, 2007
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysisJose R Arribas, Anton L Pozniak, Joel E Gallant, et al.
Antiviral Therapy|October 13, 2005
A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trialUlrik B Dragsted, Jan Gerstoft, Mike Youle, et al.
AIDS (London, England)|March 28, 2014
Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participantsFrank J Palella, Martin Fisher, Pablo Tebas, et al.
The Journal of Infectious Diseases|July 29, 2009
Virological response to initial antiretroviral regimens containing abacavir or tenofovirLoveleen Bansi, Caroline Sabin, Richard Gilson, et al.
AIDS (London, England)|June 5, 2007
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 yearsMark R Nelson, Christine Katlama, Julio S Montaner, et al.
Lancet (London, England)|December 11, 2007
Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort studyAndrew N Phillips, Clifford Leen, Alan Wilson, et al.
Pageof 21